Inspyr Therapeutics develops curative cancer therapies that are core to the principles of finding the best way to cure or extend human life. Its innovative approach to drug delivery is expected to maximize anti tumor activity while minimizing side effects. Inspyr s technology platform combines a powerful, plant derived cytotoxin thapsigargin with a prodrug delivery system that provides for the targeted release of the company s drug candidates within a tumor. Inspyr s lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the blood vessels of liver and glioblastoma cancers and in the blood vessels of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types.
Quote | Genspera Inc (OTCMKTS:NSPX)
Last: | $0.0027 |
---|---|
Change Percent: | -18.18% |
Open: | $0.0033 |
Close: | $0.0027 |
High: | $0.0034 |
Low: | $0.0026 |
Volume: | 29,638,196 |
Last Trade Date Time: | 10/11/2021 04:55:15 pm |
News | Genspera Inc (OTCMKTS:NSPX)
Inspyr Therapeutics (NSPX): FY GAAP EPS of -$0.14.Cash and restricted cash was $0.4 million and $0.02 million at December 31, 2020 and 2019, respectively.Press Release For further details see: Inspyr Therapeutics reports FY results
Implements new corporate strategy to focus on precision therapeutics for the treatment of cancer Strengthens pipeline by acquiring a proprietary portfolio of novel adenosine immuno-modulator compounds Lead asset, RT-AR001, pre-IND filing is on track for the first half of 2021 ...
Message Board Posts | Genspera Inc (OTCMKTS:NSPX)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Implements new corporate strategy to focus on precision therapeutics for the treatment of cancer Strengthens pipeline by acquiring a proprietary portfolio of novel adenosine immuno-modulator compounds Lead asset, RT-AR001, pre-IND filing is on track for the first half of 2021 ...
WESTLAKE VILLAGE, CA / ACCESSWIRE / February 18, 2021 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer, announces additional expansion of its global intellectual ...
Proceeds support the development of lead asset, RT-AR001, an adenosine receptor antagonist Funds were secured from an existing institutional investor WESTLAKE VILLAGE, CA / ACCESSWIRE / January 12, 2021 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focuse...